首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Platelet-endothelial cell adhesion molecule-1 (CD31) expression on donor endothelial cells attenuates the development of transplant arteriosclerosis.
【24h】

Platelet-endothelial cell adhesion molecule-1 (CD31) expression on donor endothelial cells attenuates the development of transplant arteriosclerosis.

机译:供体内皮细胞上的血小板-内皮细胞粘附分子-1(CD31)表达减弱了移植性动脉硬化的发展。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND Platelet-endothelial cell adhesion molecule(PECAM)-1 (CD31) is expressed on the surface of endothelial cells, platelets, monocytes, neutrophils, and certain T-cell subsets. Treatment of endothelial cells with anti-PECAM-1 antibody inhibits leukocyte transmigration. This study was designed to test the hypothesis that, in transplantation, the absence of PECAM-1 expression on donor endothelial cells would reduce the number of leukocytes transmigrating into the allograft, thereby attenuating the development of transplant arteriosclerosis.METHODS PECAM-1 and PECAM (C57BL/6/H2 ) abdominal aortic allografts were transplanted into BALB/c (H2 ) recipients; syngeneic grafts were used as controls. Aortic grafts were analyzed by performing morphometry, immunohistochemistry, and quantitative reverse transcriptase-polymerase chain reaction for the detection of intragraft cytokine mRNA production.RESULTS Intimal proliferation was exacerbated in PECAM-1 grafts (57+/-5% for PECAM-1 vs. 36+/-6% for PECAM-1; <0.005; n=6). The absence of PECAM-1 expression on donor endothelial cells did not reduce the overall number of graft-infiltrating cells significantly but instead resulted in a significant increase in infiltration by macrophages (F4/80 cells), leading to significantly elevated intragraft mRNA expression of inducible nitric oxide synthase. During the development of transplant arteriosclerosis, PECAM-1 donor endothelial cells were replaced by recipient PECAM-1 endothelial cells, a process that occurred only in the allogeneic situation. Endothelial replacement commenced 14 days after transplantation and was complete by day 30.CONCLUSIONS These data suggest that PECAM-1 expression by donor endothelial cells attenuates the development of transplant arteriosclerosis, possibly by affecting macrophage infiltration.
机译:背景技术血小板-内皮细胞粘附分子(PECAM)-1(CD31)在内皮细胞,血小板,单核细胞,嗜中性粒细胞和某些T细胞亚群的表面表达。用抗PECAM-1抗体处理内皮细胞可抑制白细胞的迁移。这项研究旨在验证以下假设:在移植中,供体内皮细胞上不存在PECAM-1表达将减少移植到同种异体移植物中的白细胞数量,从而减弱移植动脉硬化的发展.METHODS PECAM-1和PECAM(将C57BL / 6 / H2)腹主动脉移植到BALB / c(H2)受体中;同系移植物用作对照。通过形态学,免疫组织化学和定量逆转录酶-聚合酶链反应分析主动脉移植物,以检测移植物内细胞因子mRNA的产生。结果PECAM-1移植物的内膜增殖加剧(PECAM-1移植物为57 +/- 5%,而PECAM-1移植物为57 +/- 5%)。 PECAM-1为36 +/- 6%; <0.005; n = 6)。供体内皮细胞上没有PECAM-1表达不会显着减少移植物浸润细胞的总数,而是导致巨噬细胞(F4 / 80细胞)浸润的显着增加,从而导致诱导型一氧化氮合酶。在移植性动脉硬化的发展过程中,PECAM-1供体内皮细胞被受体PECAM-1内皮细胞替代,这一过程仅在同种异体情况下发生。内皮置换在移植后第14天开始,并在第30天完成。结论这些数据表明供体内皮细胞表达PECAM-1可能通过影响巨噬细胞浸润而减弱了移植性动脉硬化的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号